Literature DB >> 3143014

Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses.

D R Shaw1, M B Khazaeli, A F LoBuglio.   

Abstract

Variable region genes from mouse monoclonal antibody 17-1A (gamma 2a kappa) with specificity for human gastrointestinal malignancies have been paired with human immunoglobulin constant region genes (for heavy and light chains) to produce mouse/human chimeric immunoglobulin molecules (chIgG) for each of the four human IgG subclasses. Mouse 17-1A and the four chIgG bound similarly to two human colon cancer cell lines and had comparable binding affinities. The chIgG1 and chIgG3 molecules mediated lymphocyte and monocyte antibody-dependent cell-mediated cytotoxicity (ADCC) to colon cancer tumor cell lines comparable to that of the parent murine 17-1A. The chIgG2 and chIgG4 molecules were able to mediate ADCC to colon cancer cell lines but were clearly inferior to the chIgG1 and chIgG3 reagents. None of the chIgG antibodies or the murine 17-1A was able to mediate complement lysis of colon cancer cell lines. These studies demonstrate the ability to produce all four human IgG subclass chimeric molecules which retain biologic activity. We have confirmed the subclass preferences of human lymphocyte and monocyte Fc receptors for human IgG subclasses previously determined by studies with monomeric or aggregated IgG. These data may aid in the selection of chimeric antibodies for in vivo trials.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143014     DOI: 10.1093/jnci/80.19.1553

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  14 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 2.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.

Authors:  F J Primus; T K Pendurthi; P Hutzell; S Kashmiri; D C Slavin; R Callahan; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A.

Authors:  Y Haga; C L Sivinski; D Woo; M A Tempero
Journal:  Int J Pancreatol       Date:  1994-02

5.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

Authors:  A F LoBuglio; R H Wheeler; J Trang; A Haynes; K Rogers; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

6.  Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.

Authors:  P B Chapman; S D Gillies; A N Houghton; R M Reilly
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

Review 7.  Immunotherapy for colorectal cancer.

Authors:  K A Foon
Journal:  Curr Oncol Rep       Date:  2001-03       Impact factor: 5.945

8.  Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.

Authors:  Markus Münz; Alexander Murr; Majk Kvesic; Doris Rau; Susanne Mangold; Stefan Pflanz; John Lumsden; Jörg Volkland; Jan Fagerberg; Gert Riethmüller; Dominik Rüttinger; Peter Kufer; Patrick A Baeuerle; Tobias Raum
Journal:  Cancer Cell Int       Date:  2010-11-02       Impact factor: 5.722

9.  Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice.

Authors:  E Racila; R H Scheuermann; L J Picker; E Yefenof; T Tucker; W Chang; R Marches; N E Street; E S Vitetta; J W Uhr
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

10.  m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer.

Authors:  A M Pullyblank; P J Guillou; J R Monson
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.